Proton beam therapy is an advanced form of external radiotherapy that uses high-energy proton beams instead of photon x-ray beams or electrons. Carefully measured doses of protons are delivered to the precise area needing treatment, using the latest IBA ProteusONE technology. This ensures that the delivery of proton beam therapy is highly accurate and prevents the risk of radiation reaching surrounding healthy tissue.
Radiotherapy is used to kill and destroy cancer cells. It utilises radiation in the form of high-energy x-rays, known as photons, to kill and damage the cancerous cells and prevent their growth and reproduction. It can be used as a non-surgical option to treat cancer, and it can also be used to shrink a tumour or in combination with other treatments.
The Rutherford Cancer Centres and Elekta are bringing the next generation of personalised adaptive radiotherapy technology to oncology centres across the UK, with the new MR-linac Elekta Unity available at the Rutherford Cancer Centre North West in Liverpool in 2021.
Professor Amit Bahl is a Consultant Clinical Oncologist and Clinical Director based at The Bristol Haematology & Oncology Centre, with a special interest in breast and urological cancers, and he is widely regarded as an internationally renowned expert on all aspects of prostate cancer treatment and can discuss the intricacies of the new modalities of treatment including Proton Therapy.
Prior to his current roles, he became a Member of the Royal College of Physicians (UK) and trained in Clinical Oncology, achieving the Fellowship of the Royal College of Radiologists qualification. he has been awarded the fellowship of the Royal College of Physicians. In addition he is a current member of the National Cancer Research Institute Clinical Studies Groups for bladder cancer and chair of the penile cancer subgroup. He has also been a college tutor at the Royal College of Radiologists for 10 years and has supervised several MD theses in breast and prostate cancer research. He has previously been in the NCRI Renal and Prostate clinical studies group, and is an Executive Committee member of the British Uro-oncology group.
Professor Amit Bahl is actively involved in research into breast, prostate, bladder and penile cancers and has more than 100 publications in these research areas and have several presentations at national and international meetings. In 2012, he was awarded the Cochrane Shanks Jalil Professorship by the Royal College of Radiologists, London and is a Visiting Professor to two international centres and at the University of West of England.
Proton Beam Therapy
This consultant has received training from the Rutherford Cancer Centres in the delivery of proton beam therapy. The programme, Proton Therapy Clinical Education, in conjunction with The Perelman School of Medicine at the University of Pennsylvania and IBA, the leading proton beam therapy solutions manufacturer, involves oncologists gaining practical experience in Penn’s Roberts Proton Therapy Center – one of the world’s leading centres of proton therapy research and expertise.